Plasma biomarkers for diagnosis of Alzheimer's disease and prediction of cognitive decline in individuals with mild cognitive impairment

BACKGROUND: The last few years have seen major advances in blood biomarkers for Alzheimer's Disease (AD) with the development of ultrasensitive immunoassays, promising to transform how we diagnose, prognose, and track progression of neurodegenerative dementias. METHODS: We evaluated a panel of...

Descripción completa

Detalles Bibliográficos
Autores principales: Kivisäkk, Pia, Carlyle, Becky C., Sweeney, Thadryan, Trombetta, Bianca A., LaCasse, Kathryn, El-Mufti, Leena, Tuncali, Idil, Chibnik, Lori B., Das, Sudeshna, Scherzer, Clemens R., Johnson, Keith A., Dickerson, Bradford C., Gomez-Isla, Teresa, Blacker, Deborah, Oakley, Derek H., Frosch, Matthew P., Hyman, Bradley T., Aghvanyan, Anahit, Bathala, Pradeepthi, Campbell, Christopher, Sigal, George, Stengelin, Martin, Arnold, Steven E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10018178/
https://www.ncbi.nlm.nih.gov/pubmed/36937522
http://dx.doi.org/10.3389/fneur.2023.1069411

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10018178/
https://www.ncbi.nlm.nih.gov/pubmed/36937522
http://dx.doi.org/10.3389/fneur.2023.1069411

Ejemplares similares